K. Lau

发表

Potent, selective, and orally bioavailable inhibitors of mammalian target of rapamycin (mTOR) kinase based on a quaternary substituted dihydrofuropyrimidine.

C. Ly, S. Sideris, S. Malek, 2011, Journal of medicinal chemistry.

Potent, selective, and orally bioavailable inhibitors of the mammalian target of rapamycin kinase domain exhibiting single agent antiproliferative activity.

C. Ly, S. Sideris, S. Malek, 2012, Journal of medicinal chemistry.

Structure-based design and synthesis of potent benzothiazole inhibitors of interleukin-2 inducible T cell kinase (ITK).

Adam R. Johnson, S. Bromidge, Lawren C. Wu, 2013, Bioorganic & medicinal chemistry letters.

Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists.

S. Hymowitz, W. Fairbrother, K. Deshayes, 2009, ACS chemical biology.

Solid-phase synthesis and fluorine-18 radiolabeling of cycloRGDyK.

Ryan A. Davis, Sven H. Hausner, J. Sutcliffe, 2016, Organic & biomolecular chemistry.

Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo.

P. McEwan, J. DeVoss, A. Zarrin, 2015, Journal of medicinal chemistry.

Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Brian J. Smith, J. Baell, G. Nikolakopoulos, 2014, ACS medicinal chemistry letters.

A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.

S. Sideris, S. Malek, J. Lyssikatos, 2013, Bioorganic & medicinal chemistry letters.

Property- and structure-guided discovery of a tetrahydroindazole series of interleukin-2 inducible T-cell kinase inhibitors.

Adam R. Johnson, P. McEwan, A. Zarrin, 2014, Journal of medicinal chemistry.

Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.

C. Ly, W. Fairbrother, V. Tsui, 2010, Bioorganic & medicinal chemistry letters.

GDC-0449-a potent inhibitor of the hedgehog pathway.

K. Kotkow, L. Rubin, D. Sutherlin, 2009, Bioorganic & medicinal chemistry letters.

Discovery and Biological Profiling of Potent and Selective mTOR Inhibitor GDC-0349.

M. Belvin, C. Ly, S. Sideris, 2013, ACS medicinal chemistry letters.

Corrigendum to “GDC-0449—A potent inhibitor of the hedgehog pathway” [Bioorg. Med. Chem. Lett. 19 (2009) 5576]

K. Kotkow, L. Rubin, D. Sutherlin, 2010 .